

◆ Department of Continuing Medical Education ◆

Conflict of Interest Disclosure and Resolution & Core Competencies Multidisciplinary Approaches to Cancer Symposium October 1-3, 2026

City of Hope takes responsibility for the content, quality, and scientific integrity of this CME activity.

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Practice-Based Learning and Improvement, (2) Patient Care, (3) Systems-Based Practice, (4) Medical Knowledge, (5) Interpersonal and Communication Skills, and (6) Professionalism. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Arya Amini, MD	Consultant for AstraZeneca, and Elsevier; Grant/Research Support from AstraZeneca, Genentech, Reflexion, & Varian.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner Reviewer 1, 2, 3, 4, 5 & 6
Lauren Joyce Antrim, MD	Consultant for AstraZeneca, Dava Oncology, & Ideology Health; On the Speakers Bureau for MJH Life Sciences; Stock/Shareholder (publicly owned companies) Actuate Therapeutics, ArriVent BioPharma, BEAM Therapeutics, BeOne Medicines, Immunitybio, Legend Biotech, Elicio Therapeutics, Immuneering Corporation, Kymera Therapeutics, Revolution Medicine, Summit Therapeutics, Takeda, Tango Therapeutics, & Zai Biopharmaceutical.	None	4
Kimlin Tam Ashing, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 5 & 6
Sabarish Ayyappan, MD	Consultant for Abbvie, ADC Therapeutics, Fate Therapeutics, Genmab & Regeneron; On the Speaker's Bureau for Beigene, Genmab, & Peerview.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Azra Borogovac, MD, MS	Consultant for Kite Pharma; On the Speakers Bureau for Janssen.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Dani Castillo, MD	Consultant for Amgen, AstraZeneca, BeOne Medicines, Daiichi Sankyo & Guardant Health.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4 & 5
Jeff Chang, MD, MS	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Alex Chehrazi-Raffle, MD	Consultant for Aveo Oncology & Exelixis; Grant/Research Support from Fennec Pharmaceuticals & Tempus AI.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Pedmark (sodium thiosulfate)</i>	1, 2, 3 & 4
Alexey V. Danilov, MD, PhD	Consultant for AbbVie, AstraZeneca, BeOne Medicines, Genmab, Incyte, Janssen, Lilly Oncology, Merck, Nurix, Prelude, & Regeneron; Grant/Research Support from Abbvie, AstraZeneca, Bayer Oncology, BeOne Medicines, Bristol Myers Squibb, Cyclacel, Genmab, Lilly Oncology, MEI Pharma, Nurix, & TG Therapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Bexobrutideg, BGB-16673, epcoritamab</i>	1, 2, 3, 4, 5 & 6
John A. deVries, MD, MS	Consultant for Stryker	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 3 & 4
Marwan Fakh, MD	Consultant for AbbVie, Adagene Inc., Astellas Pharma, Bristol Myers Squibb, Delcath Systems, Inc., Exelixis, GSK, Iterion Therapeutics Inc., Janssen Research & Development, Merck, Merus N.V., Microbial Machines, Revolution Medicines, Inc., Roche/Genentech, Summit Therapeutics Inc., Taiho Oncology, Totus Medicines Inc., & Xilio Therapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 2
Lisa Anne Feldman, MD, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 6
Gabriel Fine, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Actinium-225 DOTATATE, Lead-212 DOTAMTATE, SSTR antagonists, Lu-177</i>	1, 2, 3, 4, 5 & 6
Paul Gellhaus, MD	I do not have any relevant financial relationships with any ineligible companies.	None	4
Benjamin Heyman, MD	Consultant for AbbVie, Eli Lilly, Guardant Health, Regeneron Pharmaceuticals, & Sobi; Grant/Research Support from AstraZeneca, BeOne Medicines, Century Therapeutics, & Incyte.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Sherry Hite, MOT, OTR/L	I do not have any relevant financial relationships with any ineligible companies.	None	4
Joannie M. Ivory, MD, MSPH	Consultant for AstraZeneca & Novartis.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4 & 6
Murali Janakiram, MD, MS	Consultant for Bristol Myers Squibb, Janssen, Janssen-Investigator Response Committee, Legend Biotechnology; Grant/Research Support from Bristol Myers Squibb, Fate Therapeutics, & Janssen.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: ELRANTAMAB, LINVOSLTMAB</i>	1, 2, 3, 4, 5 & 6
Veronica Jones, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Irene Kang, MD	Consultant for AstraZeneca, BioNTech, Daiichi Sankyo, Gilead Sciences, Menarini Stemline, Novartis, & Pfizer; Grant/Research Support from Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 4
Jonathan Kessler, MD	Consultant for Boston Scientific, RenovoRX & Varian.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	Planner 1, 2, 3 & 4
Clayton Stephen Lau, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Lisa X. Lee, MD	Consultant for Legend Biotechnology.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Planner Reviewer Moderator
Christine Lovly, MD, PhD	Consultant for AbbVie, Amgen, AnHeart, Astra Zeneca, Black Diamond, BMS, Boehringer Ingelheim, Daiichi Sankyo, Exact, Foresight, Foundation Medicine, Guardant, Genentech, Gilead, Guardant, Immunity Bio, Jazz, JNJ, Merck, Nuvalent, Nuvation, Onvivo, Pfizer, Regeneron, Summit, Takeda, Taiho, & Tempus.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Ellie Maghami, MD	I do not have any relevant financial relationships with any ineligible companies.	None	2, 4, 5 & 6
Sean Maroongroge, MD, MBA	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4 & 5
Amy McKnight, MSN, RN	I do not have any relevant financial relationships with any ineligible companies.	None	Planner Moderator
Badri Modi, MD	Consultant for Sun Pharmaceuticals; On the Speaker's Bureau for Regeneron.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	4
Monica Munaretto, MSN, RN	I do not have any relevant financial relationships with any ineligible companies.	None	Planner Moderator

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Krupal Patel, MD, MSc	Consultant for Johnson & Johnson, & Rakuten Medical; Stock/Shareholder (publicly owned companies) Allogene Therapeutics, Bristol Myers Squibb, Eli Lilly, Milestone Pharmaceuticals, Pfizer, Privo Technologies, Regeneron & Viking Therapeutics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2 & 4
Mustafa Raoof, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Planner 1, 2 & 4
Dan J. Raz, MD, MAS	Grant/Research Support from AstraZeneca.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 4 & 5
Hope S. Rugo, MD	Consultant for BioNTech, Bristol Myers Squibb, Helsinn, & Nap; and Grant/Research Support to UCSF from AstraZeneca, Ambryx, Daiichi Sankyo, Eli Lilly, F.Hoffman-LaRoche/Genentech, Gilead Sciences, Merck & Co., Novartis, Pfizer, & Stemline Therapeutics; Grant/Research Support from from ALX Oncology, Bicycle Therapeutics, F.Hoffman-La Roche/Genentech, Mabwell, Merck & Co., Pfizer, PhoenixMD, Relay Therapeutics, & Stemline Therapeutics	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: T-DXd, Zanidatimab, Tucatinib, novel HER2 ADCs</i>	1, 4 & 6
Crystal Saavedra, BA	I do not have any relevant financial relationships with any ineligible companies.	None	Planner
Amanda Schwer, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4
Aditya Shreenivas, MD, MS	Consultant for Bayer, Fennec Pharma, Fulgent, Genmab, Lilly, & Taiho; Grant/Research Support from Caris Life Sciences & Foundation One.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Petosumtamab, FID007, CRB701</i>	1, 2, 3, 4, 5 & 6
Gagandeep Singh, MD	Consultant for Cook Medical.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Joo Song, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Planner 1, 2, 3, 4, 5 & 6
Walter Stadler, MD	Consultant for AstraZeneca, Aveo Oncology, Bayer, Caremark/CVS, EMD Serono, Fortress Biotech, Merck, Pfizer, Treadwell Therapeutics (DSMB), and XenCor; Grant/Research Support from Abbvie, Amgen, AstraZeneca, Astellas (Medivation), Bayer, Bristol Myers Squibb, Boehringer-Ingelheim, Calithera, Corvus, Eisai, Exelixis, Genentech (Roche), GSK, Johnson & Johnson (Janssen), Merck, Novartis, Pfizer, Seattle Genetics, X4Pharmaceuticals & Xencor; Stock/Shareholder of (publicly owned company) Fortress Biotech.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: PSMA-targeted actinium-225; ABBV-969, Xaluritamid (AMG 509), ARV-766, possibly other investigational agents</i>	1, 2, 3 & 4

Conference Faculty	Commercial Interest	Conflict/ Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Manisha Trivedi, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Christina Yeon, MD, MHM	I do not have any relevant financial relationships with any ineligible companies.	None	Planner Moderator
Ali Zhumkhawala, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 4

1. The ACCME defines “relevant” financial relationships” as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an “Ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.